Avidity Biosciences Inc [NASDAQ: RNA] surged by $0.86 during the normal trading session on Tuesday and reaching a high of $70.76 during the day while it closed the day at $70.7.
Avidity Biosciences Inc stock has also gained 1.25% of its value over the past 7 days. However, RNA stock has inclined by 53.20% in the 3 months of the year. Over the past six months meanwhile, it has gained 136.61% and gained 48.81% year-on date.
The market cap for RNA stock reached $10.32 billion, with 146.77 million shares outstanding and 133.97 million shares in the current float. Compared to the average trading volume of 5.10M shares, RNA reached a trading volume of 5694973 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Avidity Biosciences Inc [RNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RNA shares is $73.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RNA stock is a recommendation set at 2.47. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Roth Capital have made an estimate for Avidity Biosciences Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 17, 2025. While these analysts kept the previous recommendation, Goldman raised their target price to Buy. The new note on the price target was released on July 10, 2025, representing the official price target for Avidity Biosciences Inc stock. Previously, the target price had yet another raise to $50, while Bernstein analysts kept a Outperform rating on RNA stock.
The Price to Book ratio for the last quarter was 5.50, with the Price to Cash per share for the same quarter was set at 12.86.
RNA stock trade performance evaluation
Avidity Biosciences Inc [RNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.25. With this latest performance, RNA shares gained by 44.40% in over the last four-week period, additionally plugging by 136.61% over the last 6 months – not to mention a rise of 143.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RNA stock in for the last two-week period is set at 80.43, with the RSI for the last a single of trading hit 1.47, and the three-weeks RSI is set at 2.13 for Avidity Biosciences Inc [RNA]. The present Moving Average for the last 50 days of trading for this stock 51.55, while it was recorded at 69.99 for the last single week of trading, and 37.65 for the last 200 days.
Avidity Biosciences Inc [RNA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Avidity Biosciences Inc [RNA] shares currently have an operating margin of -2934.90% and a Gross Margin at 83.74%. Avidity Biosciences Inc’s Net Margin is presently recorded at -2634.59%.
Avidity Biosciences Inc (RNA) Capital Structure & Debt Analysis
According to recent financial data for Avidity Biosciences Inc. ( RNA), the Return on Equity (ROE) stands at -32.44%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -29.13%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Avidity Biosciences Inc’s Return on Invested Capital (ROIC) is -28.45%, showcasing its effectiveness in deploying capital for earnings.
Avidity Biosciences Inc (RNA) Efficiency & Liquidity Metrics
Based on Avidity Biosciences Inc’s (RNA) latest financial statements, the Debt-to-Equity Ratio is 0.03%, indicating its reliance on debt financing relative to shareholder equity.
Avidity Biosciences Inc (RNA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Avidity Biosciences Inc. (RNA) effectively leverages its workforce, generating an average of -$1406112.53 per employee. The company’s liquidity position is robust, with a Current Ratio of 11.57% and a Quick Ratio of 11.57%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Avidity Biosciences Inc [RNA] stock
With the latest financial reports released by the company, Avidity Biosciences Inc posted -0.8/share EPS, while the average EPS was predicted by analysts to be reported at -0.78/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Avidity Biosciences Inc go to -10.53%.
Avidity Biosciences Inc [RNA]: Institutional Ownership
There are presently around $94.94%, or 99.08%% of RNA stock, in the hands of institutional investors. The top three institutional holders of RNA stocks are: FMR LLC with ownership of 16.16 million shares, which is approximately 15.1121%. PRICE T ROWE ASSOCIATES INC /MD/, holding 10.92 million shares of the stock with an approximate value of $$445.94 million in RNA stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $$359.76 million in RNA stock with ownership which is approximately 8.2362%.
